gip/glp-1 ra The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Indications for GLP-1/GIP RA Summary

Therefore, before recommending GLP-1 therapy broadly in normal-weight populations, policymakers and clinicians must carefully weigh cost-effectiveness alongside clinical outcomes

This is what evidence-based ECS science looks like: rigorous mechanistic validation, clinical relevance, decades of safety precedent, and therapeutic rationale independent of phytocannabinoid delivery

In addition to its glucose-lowering effects, Ozempic also facilitates weight loss by inducing satiety and diminishing appetite, resulting in a decrease in daily calorie intake

GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans Posted on August 21, 2025 A Snippet From Our GLP-1 Spotlight Webinar Key Points Employers tend to view obesity as a chronic condition, while health plans lean slightly toward viewing obesity as a lifestyle condition